Neurocysticercosis: Clinical Trials

4 trials for Neurocysticercosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 withdrawn. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Withdrawn 1

Follow Neurocysticercosis: new trials by email Literature Review of Neurocysticercosis trials Research Report on Neurocysticercosis

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single Ascending Dose Safety Study of Oxfendazole
oxfendazole, placebo - Tenia Solium Infection
Phase 1WithdrawnJohns Hopkins Bloomberg School of Public Health2016-08-012016-08-30
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
Oxfendazole, Placebo - Neurocysticercosis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)702014-11-172020-11-02
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
[F-18]FBR - Neurocysticercosis, Healthy
Phase 1CompletedNational Institute of Mental Health (NIMH)242007-09-042018-07-05
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
[C-11]PBR28 - Neurocysticercosis, Healthy
Phase 1CompletedNational Institute of Mental Health (NIMH)182007-09-042019-12-12

Narrower conditions

Taeniasis (4)  ·  Epilepsy (2)  ·  Neuroinflammatory Diseases (2)

Broader conditions

Central Nervous System Diseases (4)  ·  Central Nervous System Helminthiasis (4)  ·  Central Nervous System Infections (4)  ·  Central Nervous System Parasitic Infections (4)  ·  Cestode Infections (4)  ·  Cysticercosis (4)  ·  Helminthiasis (4)  ·  Infections (4)  ·  Nervous System Diseases (4)  ·  Parasitic Diseases (4)  ·  Brain Diseases (2)  ·  Inflammation (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)

Interventions

oxfendazole (2)

Sponsors

National Institute of Mental Health (NIMH) (2)  ·  Johns Hopkins Bloomberg School of Public Health (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)

Countries

United States (3)

Top investigators

Masahiro Fujita, M.D. (2)  ·  Robert H Gilman, MD (1)

Results publications

PMID 29749279, PMID 30745383, PMID 8615453, PMID 9364715, PMID 9840607